MDMA-assisted psychotherapy for PTSD in New Zealand

Within the wider field of psychedelic-assisted psychotherapy, MDMA-assisted treatment is a structured process rather than a stand-alone prescription. The medicine session is held within a course of clinical care that includes preparation beforehand and integration afterwards. The umbrella therapy page explains that course of care in full.

MDMA belongs to a different pharmacological class from classic psychedelics such as psilocybin. It prompts a release of serotonin, noradrenaline, and oxytocin that tends to reduce fear and increase feelings of safety and connection, which the therapy session uses to support a person in approaching traumatic memories rather than avoiding them. This is a proposed mechanism rather than settled science.

The current approval concerns eligible adults with PTSD. It does not mean everyone with PTSD is suitable for MDMA-assisted psychotherapy. Psychiatric history, physical health, current medicines, substance use, available support, and a person’s preferences all form part of the assessment.

Some psychiatric, medical, or medicine-related factors may make the treatment unsuitable. If that is the case, the clinical conversation should explain why and consider sensible alternatives.

• It permits named psychiatrists to prescribe within the approved treatment programme.
• It does not make MDMA an approved medicine in New Zealand.
• It does not create open prescribing by other clinicians.
• It does not guarantee treatment after referral or assessment.
• Legal approval, medicine supply, informed consent, and programme requirements must all be met before treatment.

The Ministry of Health announcement describes the two practitioner-specific New Zealand approvals and their safeguards. Medsafe publishes separate guidance for applications to prescribe psychedelics. Two randomised Phase 3 trials published in Nature Medicineform part of the international evidence base; trial findings do not establish medicine approval or predict an individual outcome. Internationally, the treatment remains under regulatory review: the United States FDA requested further evidence in 2024 and has not yet reached a decision, and Australia’s TGA provides the only comparable prescriber pathway outside New Zealand.